{"a":[{"_":"Novartis gains full FDA nod for Fabhalta in kidney disorder IgAN","$":{"href":"/pharma/novartis-gains-full-fda-nod-fabhalta-kidney-disorder-igan","hreflang":"en"}}]}
RegulatoryapprovedFabhaltaPositive
AI Analysis
Summary
The FDA has converted Novartis' accelerated approval for Fabhalta into full approval for treating immunoglobulin A nephropathy (IgAN), indicating the drug's efficacy in slowing kidney function decline in at-risk adults.
Outcome Details
FDA converted accelerated approval to full approval for Fabhalta to treat IgAN and slow kidney function decline in adults at risk of disease progression
Importance:8/10
Sentiment:
0.90
FDA approvalaccelerated approval conversionkidney diseaseIgAN
Related Companies
Read the original article
Published by FiercePharma on July 17, 2026 11:02 AM